Search the Newsreel

Haleon plc Non-GAAP EPS of 10.30p, revenue of £5.6B; reaffirms FY outlook

* Haleon plc press release [https://www.haleon.com/news/press-releases/financial/2026/2026-half-year-results] (HLN [https://seekingalpha.com/symbol/HLN]): 1H Non-GAAP EPS of 10.30p. * Revenue of £5.6B, up 2.2% Y/Y. * Free cash flow: H1 £769m, up £35m supported by strong operating leverage * Net debt/Adjusted EBITDA: 2.5x at end of H1, in line …

Haleon Raises Interim Dividend Following First-Half 2026 Results

Haleon plc has announced a 9% increase in its interim dividend for the first half of 2026, setting it at 2.4 pence per ordinary share. The company reaffirmed its policy of growing dividends in line with adjusted earnings and expressed a positive outlook for …

Haleon (LON:HLN) Releases Earnings Results

Haleon Sees Volume Recovery From North America, and Margins Continue to Improve

Haleon, one of the leading consumer healthcare companies globally, is experiencing a recovery in volume from North America, with margins showing continuous improvement. The company has streamlined its operations by divesting non-strategic brands and optimizing its manufacturing and distribution networks. This strategic optimization positions …

Sensodyne maker Haleon slips as sales growth concerns overshadow profit beat

By Raechel Thankam Job and Richa Naidu July 30 (Reuters) - Sluggish European demand and weak respiratory sales raised doubts on Thursday about whether Haleon can ‌meet its sales targets, sending shares in the consumer health company lower despite ‌better-than-expected first-half profit. The British …

Haleon posts in-line quarterly sales growth as oral health, North America drive demand

Haleon reported a 3.1% organic sales growth in the second quarter, matching estimates, fueled by strong demand for its oral health products and accelerated growth in North America. The company reaffirmed its 2026 forecast for 3% to 5% organic revenue growth and high-single-digit adjusted …

Haleon plc Revenue Breakdown – NYSE:HLN

Haleon PLC (LSE:HLN) Q2 2026 Earnings Report Preview: What to Look For

HLN|Haleon PLC|Price:10.280|Chg%:+0.340

This article provides a comprehensive stock analysis of Haleon PLC (HLN), highlighting its healthy fundamentals, high growth potential, and fairly valued status within the Pharmaceuticals industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price of $10.63. The …

Haleon PLC Sponsored ADR Revenue Breakdown – HAM:H6D

Haleon PLC Sponsored ADR (HAM:H6D) generated 12.71 billion EUR in revenue last year. The Oral Health segment was its top-performing division, contributing 3.88 billion EUR, while the EMEA and Latin America region provided the greatest geographical contribution at 5.15 billion EUR. This information highlights …

Haleon rises Monday, outperforms market

Haleon PLC's shares increased by 1.84% to £3.70 on Monday, outperforming the FTSE 100 Index which rose 0.42%. The company's stock closed 11.03% below its 52-week high of £4.16 reached on February 18th.

Haleon PLC (HLN) Cash Flow

This article provides an in-depth look at Haleon PLC's cash flow statements, including operating, investing, and financing activities. It details specific financial figures for FY2023Q4, such as operating cash flow of $1.49 billion and free cash flow of $1.24 billion. The content also includes …

Haleon PLC (HLN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Haleon PLC (HLN), listing its major individual shareholders and their respective proportions. It also provides a breakdown of shareholder types, institutional holdings over recent quarters, and recent shareholder activity with changes in ownership. Additionally, it lists several …

Haleon stock holds steady as consumer health margins support valuation

Haleon stock is maintaining stability due to strong consumer health margins, with its 2023 annual report showing £11.3 billion in revenue and modest growth. The company is focused on deleveraging, consistent dividend payouts, and expanding operating margins through cost efficiencies and a high-margin product …

Haleon plc American Depositary Shares (Each representing two) (HLN) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for Haleon plc American Depositary Shares (HLN) on the NYSE. It displays the current stock price, daily change, and offers candlestick line charts for various timeframes. The page also includes sections for analyst ratings and earnings information, …

Haleon PLC (HLN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Haleon PLC (HLN), segmenting its revenue by business, region, and financial year. The data shows contributions from various product categories like oral health and pain relief, and also outlines regional revenue proportions including Rest of the …

Haleon PLC (HLN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a detailed historical overview of dividend payouts for Haleon PLC (HLN), including ex-dividend dates, record dates, payment dates, and dividend amounts. It notes that Haleon PLC has distributed a total of 570.00M USD in dividends over the past five years. The …

Haleon PLC (HLN) Institutional Confidence

Haleon PLC (HLN) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 5.63% quarter-over-quarter to 12.97%. First Eagle Investment is the largest institutional shareholder, holding 105.83M shares, representing 2.24% of …

Haleon stock trades steadily as consumer health revenue grows and margin focus intensifies

Haleon stock demonstrates stability driven by consistent consumer health demand and effective margin management. The company reported roughly GBP 11 billion in revenue for full year 2023, accompanied by solid organic growth and adjusted operating margins in the mid to high teens. Strong free …

Haleon (HLN) 21st Annual dbAccess Global Consumer Conference 2024 Summary

This article summarizes Haleon's presentation at the 21st Annual dbAccess Global Consumer Conference 2024, highlighting the strong performance and strategic growth in its EMEA and LATAM regions. Key drivers include a balanced portfolio of power brands like Panadol, Voltaren, Sensodyne, and Centrum, along with …

Haleon (HLN) to Announce Quarterly Earnings on Thursday

Haleon stock trades steadily as consumer health group highlights resilient cash generation

Haleon stock is trading steadily due to the consumer health group's emphasis on cash generation and debt reduction. The company reported mid-single-digit organic revenue growth in 2023, maintained adjusted operating margins, and is guiding for similar growth in 2024. Haleon prioritizes deleveraging and aims …

Haleon stock trades steadily as consumer health earnings and cash flow support valuation

Haleon stock shows steady performance driven by strong consumer health earnings and effective debt reduction following its GSK spin-off. In fiscal 2023, the company reported €11 billion in revenue and €1.5 billion in free cash flow, significantly reducing net debt to around €8 billion. …

Haleon stock trades steady as oral health and pain relief drive growth

Haleon stock demonstrates steady growth driven by its oral health and pain relief segments, with 2023 revenues up in the low single-digit percentage range to approximately GBP 11 billion. The company achieved margin expansion through disciplined cost management and a focus on higher-margin branded …

Haleon stock trades steadily as consumer health group lifts earnings and organic revenue

Haleon stock shows steady performance driven by rising organic revenue, expanding margins, and consistent dividends following its demerger from GSK. The consumer health company reported mid-single-digit organic growth in fiscal 2023, attributed to balanced volume, mix, and pricing increases across its diverse portfolio. Haleon …

Haleon (HLN) H1 2024 (Q&A) earnings summary

Haleon (HLN) reported a strong H1 2024 with 3.5% organic revenue growth and 11% organic operating profit growth, driven by Power Brands like Sensodyne and Centrum. The company updated its FY 2024 guidance to 4-6% organic revenue growth and high single-digit organic operating profit …

Haleon (HLN) 23rd annual dbAccess Global Consumer Conference Summary

Haleon (HLN) presented at the 23rd annual dbAccess Global Consumer Conference, highlighting its strategic priorities, transformation efforts, and global performance. The company has focused on business continuity, debt reduction, and rebuilding leadership post-separation, with a strong emphasis on growth and productivity initiatives aimed at …

Haleon (HLN) Q4 2024 Earnings: EPS Beats Estimates by 7.2%, Stock Modestly Lower - Trough Earnings Signal

Haleon stock trades steady as consumer health group highlights resilient cash generation

Haleon's stock performance reflects its steady revenue growth and strong cash generation, driven by its diverse portfolio in consumer health. The company reported over GBP 11 billion in annual revenue for fiscal 2024, significant adjusted operating profit, and substantial free cash flow, contributing to …